SCHEMBL283586

SCHEMBL283586

CC(C)(C)OC(=O)[C@H](N)CCC(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
PMP22 Q01453 2/20 0.50
ALOX15 P16050 1/20 0.50
BLM P54132 1/20 0.50
LTA4H P09960 1/20 0.43
DPP4 P27487 1/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
NOS1 P29475 2/20 0.41
NOS3 P29474 1/20 0.41
NOS2 P35228 1/20 0.41
CYP1A2 P05177 2/20 0.33
GRM8 O00222 1/20 0.33
GRM6 O15303 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GSR P00390 1/20 0.33
GRIK1 P39086 1/20 0.33
GRM5 P41594 1/20 0.33
GRIA1 P42261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594919 1.00 KMT2A (0.50) KMT2APMP22ALOX15BLMLTA4H
SCHEMBL1261014 1.00 KMT2A (0.50) KMT2APMP22ALOX15BLMLTA4H
Hydrochloric Acid SCHEMBL2282696 0.98 PMP22 (0.48) KMT2APMP22ALOX15BLMLTA4H
Hydrochloric Acid SCHEMBL2286046 0.98 PMP22 (0.48) KMT2APMP22ALOX15BLMLTA4H
Hydrochloric Acid SCHEMBL594918 0.98 PMP22 (0.48) KMT2APMP22ALOX15BLMLTA4H
SCHEMBL6555625 0.86 ALOX15 (0.44) KMT2APMP22ALOX15BLMLTA4H
SCHEMBL3294154 0.86 NOS1 (0.42) KMT2APMP22LTA4HNOS1NOS3
SCHEMBL595358 0.85 LTA4H (0.41) KMT2APMP22ALOX15BLMLTA4H
SCHEMBL23080922 0.85 LTA4H (0.43) KMT2APMP22ALOX15BLMLTA4H
SCHEMBL561334 0.85 CYP1A2 (0.52) KMT2ABLMLTA4HDPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822093-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2017-11-21 US claimed
US-20160297791-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2016-10-13 US claimed
EP-2380887-B1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORP (US) 2013-08-07 EP claimed
EP-2380887-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds Celgene Corporation (US) 2011-10-26 EP claimed
US-20110224440-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION 2011-09-15 US claimed
US-20070004920-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION AN ORGNIZATION OF THE STATE NEW JERSEY (US) 2007-01-04 US claimed
US-10266514-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2019-04-23 US disclosed
EP-0925294-B3 SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS CELGENE CORP (US) 2018-07-04 EP disclosed
US-20180044318-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2018-02-15 US disclosed
US-20170369471-A1 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2017-12-28 US disclosed
US-9822093-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2017-11-21 US disclosed
EP-3239144-A1 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS Celgene Corporation (US) 2017-11-01 EP disclosed
US-9732064-B2 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2017-08-15 US disclosed
US-20020045643-A1 Isoindolines, method of use, and pharmaceutical compositions MULLER GEORGE W (US) 2002-04-18 US disclosed
US-6335349-B1 AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES CELGENE CORPORATION 2002-01-01 US disclosed
US-6316471-B1 TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES CELGENE CORPORATION 2001-11-13 US disclosed
US-6281230-B1 TREATING INFLAMMATION, INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE IN A MAMMAL CELGENE CORPORATION 2001-08-28 US disclosed
CN-1239959-A Subsitutted 2(2,6-dioxopiperidin-3-yl) phthalimides and -1-xoisoindolines and method of reducing TNF-alpha levels CELGENE CORP (US) 1999-12-29 CN disclosed
EP-0925294-A1 SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS CELGENE CORPORATION (US) 1999-06-30 EP disclosed
WO-1998003502-A1 SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS CELGENE CORPORATION (US) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224440-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS TNF, TRAF2, IL1A KMT2A 3715/4885PMP22 4232/4885ALOX15 1018/4885
US-20160297791-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS TNF, TRAF2, IL1A KMT2A 3715/4885PMP22 4232/4885ALOX15 1018/4885
US-10266514-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds TNF, TRAF2, IL1A KMT2A 3715/4885PMP22 4232/4885ALOX15 1018/4885
US-20020045643-A1 Isoindolines, method of use, and pharmaceutical compositions TNF, OPRK1, OPRD1 KMT2A 3335/4885PMP22 2330/4885ALOX15 2222/4885
US-20070004920-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds TNF, DHPS, IL1A KMT2A 3682/4885PMP22 3884/4885ALOX15 1244/4885
US-20170369471-A1 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME IL5, IL6, PGF KMT2A 4830/4885PMP22 3813/4885ALOX15 1420/4885
US-20180044318-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS TNF, TRAF2, IL1A KMT2A 3715/4885PMP22 4232/4885ALOX15 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.